{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoietin-stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD)","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-3-open-label-randomized-study-to-compare-the-efficacy-and-safety-of-luspatercept-ace-536-vs-epoetin-alfa-for-the-treatment-of-anemia-due-to-revised-international-prognostic-scoring-system\/#breadcrumbitem"}]}